Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants

OBJECTIVES:

Primary

- To assess the effectiveness of bimatoprost ophthalmic solution in expediting regrowth
of eyebrows and eyelashes in patients who have undergone chemotherapy for breast cancer
and in increasing eyebrow growth in healthy participants with no known underlying
disease as assessed by two physicians and an aesthetics expert on a scale of 0-4.

Secondary

- To assess the effectiveness of this treatment as assessed by patient self-report on a
scale of 0-4.

- To assess the psychological impact of this treatment as assessed by patient-completed
questionnaires.

OUTLINE: Patients are randomized to 1 of 2 intervention arms.

- Arm I: Patients apply topical bimatoprost ophthalmic solution to base of upper eyelid
margins OR to eyebrow region once daily for 4 months in the absence of unacceptable
toxicity.

- Arm II: Patients apply topical placebo solution to base of upper eyelid margins OR to
eyebrow region once daily for 4 months in the absence of unacceptable toxicity.

Patients complete questionnaires at baseline and monthly for 5 months about changes in
eyebrows/eyelashes, side effects of treatment, and the psychological impact of treatment.
Photographs of eyebrows or eyelashes and surrounding skin are taken at baseline and monthly
for 5 months and reviewed by a physician and aesthetics expert.

After completion of study treatment, patients are followed up at 1 month.

Inclusion Criteria:

- Meets 1 of the following criteria:

- Diagnosis of breast cancer (group 1)

- Completed chemotherapy within the past month that has resulted in eyebrow alopecia or
eyelash hypotrichosis

- Eyebrow score of 0-2 or eyelash score of 0-2 on the study's qualitative eyebrow or
eyelash growth chart

- Has no known underlying disease (group 2)

- Desires thicker, fuller, or more numerous eyebrows

Exclusion criteria

- pregnant

- does not Speak a language adequately covered by study translator services

- cognitive impairment

- history of trauma or burn to the eyebrow region, alopecia areata, or trichotillomania

- known diagnoses possibly underlying or contributing to the state of the eyebrows
including, but not limited to, telogen effluvium or anagen effluvium (group 2)

- active ocular disease (group 1)

- thyroid hormone level abnormalities (group 2)

- More than 2 years since prior ocular surgery (group 1)

- prior topical medication for increasing eyebrow growth within 30 days od starting
study treatment

- concomitant chemotherapy for the treatment of cancer (group 1)

- concomitant therapy for eyelash or eyebrow growth